Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data.

被引：0
|
作者：
Curtis, Jeffrey R. [1 ]
Churchill, Melvin [2 ]
Kivitz, Alan [3 ]
Gauer, Laura [4 ]
Herrem, Christopher [4 ]
Carter, David [5 ]
Melin, Jeffrey [4 ]
Yazici, Yusuf [6 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Arthrit Ctr Nebraska, Lincoln, NE USA
[3] Altoona Arthrit & Osteoporosis Ctr, Duncansville, PA USA
[4] UCB Pharma, Smyrna, GA USA
[5] UCB Pharma, Brussels, Belgium
[6] NYU, Hosp Joint Dis, New York, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1844
引用
收藏
页码：S811 / S811
页数：1
相关论文
共 50 条
  • [1] Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
    Annelise Madison
    Barbara L. Andersen
    Ali Ajam
    Arthritis Research & Therapy, 21
  • [2] Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial"
    Madison, Annelise
    Andersen, Barbara L.
    Ajam, Ali
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [3] A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial
    Jeffrey R. Curtis
    Christopher Herrem
    ’Matladi N. Ndlovu
    Cathy O’Brien
    Yusuf Yazici
    Arthritis Research & Therapy, 19
  • [4] A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial
    Curtis, Jeffrey R.
    Herrem, Christopher
    Ndlovu, Matladi N.
    O'Brien, Cathy
    Yazici, Yusuf
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [5] CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
    Tanaka, Y.
    Li, Z.
    Inanc, N.
    Xavier, R.
    Tilt, N.
    Cara, C.
    Saadoun, C.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 267 - 268
  • [6] DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA
    Bykerk, V.
    Gottlieb, A. B.
    Reich, K.
    Tanaka, Y.
    Winthrop, K.
    Popova, C.
    Tilt, N.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 617 - 617
  • [7] Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial
    Berenbaum, Francis
    Thao Pham
    Claudepierre, Pascal
    de Chalus, Thibault
    Joubert, Jean-Michel
    Saadoun, Carine
    Franca, Lionel Riou
    Fautrel, Bruno
    JOINT BONE SPINE, 2018, 85 (01) : 54 - 59
  • [8] Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
    Vivian P. Bykerk
    Peter Nash
    David Nicholls
    Yoshiya Tanaka
    Kevin Winthrop
    Christina Popova
    Nicola Tilt
    Derek Haaland
    Rheumatology and Therapy, 2023, 10 : 693 - 706
  • [9] Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
    Bykerk, Vivian P. P.
    Nash, Peter
    Nicholls, David
    Tanaka, Yoshiya
    Winthrop, Kevin
    Popova, Christina
    Tilt, Nicola
    Haaland, Derek
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 693 - 706
  • [10] Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
    Schenker, Hannah
    Hess, Andreas
    Konerth, Laura
    Sergeeva, Marina
    Prade, Jutta
    Kleyer, Arnd
    Reiser, Michaela
    Hueber, Axel J.
    Englbrecht, Matthias
    Feist, Eugen
    Voll, Reinhard
    Bannert, Bettina
    Baerwald, C.
    Roesch, Julie
    Doerfler, Arnd
    da Silva, Jose Antonio P.
    Damjanov, Nemanja
    Schett, Georg
    Rech, Juergen
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345